Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression.

Item

http://www.wikidata.org/entity/Q38381405

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression.

@en

type

Item

label

Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression.

@en

prefLabel

Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression.

@en

P1476

Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression

@en

P2093

Amparo Tricas

http://www.w3.org/2001/XMLSchema#string

Ana Gonzalez-Cordon

http://www.w3.org/2001/XMLSchema#string

Berta Torres

http://www.w3.org/2001/XMLSchema#string

Esteban Martinez

http://www.w3.org/2001/XMLSchema#string

Federico Garcia

http://www.w3.org/2001/XMLSchema#string

Jhon Rojas

http://www.w3.org/2001/XMLSchema#string

Jose M Gatell

http://www.w3.org/2001/XMLSchema#string

Josep Mallolas

http://www.w3.org/2001/XMLSchema#string

José L Blanco

http://www.w3.org/2001/XMLSchema#string

Laura Moreno

http://www.w3.org/2001/XMLSchema#string

P2860

The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?

Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection.

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.

Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial.

Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients.

Emerging concepts on the use of antiretroviral therapy in older adults living with HIV infection.

Current state and limitations of daily oral therapy for treatment.

Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.

P304

1975-1981

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKW078

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Maria Angeles Marcos

P577

2016-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27021341

http://www.w3.org/2001/XMLSchema#string